
2.03 Delayed Data As of Sep 29 | ![]() Today’s Change | 1.86 Today|||52-Week Range 3.15 | -12.88% Year-to-Date |
The 5 analysts offering 12-month price forecasts for Arbutus Biopharma Corp have a median target of 4.00, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a +97.04% increase from the last price of 2.03.
The current consensus among 5 polled investment analysts is to Buy stock in Arbutus Biopharma Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.